Development of conditionally replicating adenovirus that treats human ES/iPS-derived tumor
Project/Area Number |
23659159
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
General medical chemistry
|
Research Institution | Kagoshima University |
Principal Investigator |
KOSAI kenichirou 鹿児島大学, 医歯(薬)学総合研究科, 教授 (90258418)
|
Co-Investigator(Kenkyū-buntansha) |
IRIE Rie 鹿児島大学, 大学院・医歯学総合研究科, 助教 (90381178)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | 再生医学 |
Research Abstract |
The tumor that is derived from the contaminated undifferentiated-cells is the major obstacle to the clinical application of human ES and/or iPS cell-based regenerative medicine. Here we developed a novel methodology that might conquer this obstacle to some degrees using m-CRA (conditionally replicating adenovirus with multiple tumor-specific factors), which we had initially developed for treating cancer. This methodology is not only a scientifically novel and original but also meaningful in terms of facilitating clinical development of these sorts of innovative therapy.
|
Report
(4 results)
Research Products
(55 results)